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To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in
patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40mg)
and TMZ (50–200mgm
 2) orally for 5 consecutive days every 4 weeks. Response was determined every two cycles.
Pharmacokinetics of lomeguatrib and TMZ as well as their pharmacodynamic effects in peripheral blood mononuclear cells (PBMC)
were determined. Nineteen patients received 49 cycles of treatments. Despite consistent depletion of O
6-methylguanine-DNA
methyltransferase in PBMC, none of the patients responded to treatment. Three patients had stable disease, one for the duration of
the study, and no fall in carcinoembryonic antigen was observed in any patient. Median time to progression was 50 days. The
commonest adverse effects were gastrointestinal and haematological and these were comparable to those of TMZ when given alone.
This combination of lomeguatrib and TMZ is not efficacious in metastatic colorectal cancer. If further studies are to be performed,
emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated.
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Colorectal cancer is the second most common cause of death in
cancer patients in the Western world (Lieberman, 2006). Current
treatment for colorectal cancer is dependent on the stage of the
disease and is usually in the form of surgery, radiotherapy or
chemotherapy. The most commonly used chemotherapy is a
combination of 5-fluorouracil (5-FU) and leucovorin (1990). In
stage IV metastatic disease, this enables survival for just over 1
year (Thirion et al, 2004). More recently, studies have been
conducted in this patient group using oxaliplatin and irinotecan
combined with 5-FU and leucovorin (de Gramont et al, 2000;
Douillard et al, 2000). Sequential use of these agents has improved
median survival to greater than 20 months, but response rates for
second- or third-line treatments in metastatic colorectal cancer
remain low (Tournigand et al, 2004; Saletti and Cavalli, 2006).
Temozolomide (TMZ) is an oral alkylating agent with broad
spectrum of antitumour activity and relatively low toxicity (Payne
et al, 2005). It has been shown to inhibit the growth of human
tumour xenografts in vitro and is active in human colorectal lines
(Friedman et al, 1995; Liu et al, 1996). Cytoxicity of TMZ is
thought to be mediated principally through the methylation of
DNA at the O
6 position of guanine (Tisdale, 1987; Baer et al, 1993;
D’Atri et al, 1995). Efficacy against colorectal cancer has not been
extensively studied in clinical trials. In a phase I study of TMZ, 12
out of 22 patients had metastatic colorectal cancer and there was
one partial response in this group, suggesting considerable tumour
resistance to treatment (Spiro et al, 2001).
Tumour cell resistance to O
6-alkylating agents is conferred by
the DNA repair protein O
6-methlylguanine-DNA alkyltransferase
(MGMT) (D’Incalci et al, 1988; Pegg, 1990). This removes the alkyl
group from guanine in a stoichiometric autoinactivating reaction
before subsequent rounds of replication can give rise to apoptosis.
Cell death after TMZ treatment also depends upon recognition of
O
6-guanine/thymine mispairs by the mismatch repair (MMR)
pathway (Souliotis et al, 1991). Tumour cells frequently express a
high level of MGMT. Treatment with O
6-alkylating drugs is likely
to be more effective when they are used in combination with drugs
that inactivate the repair protein.
Lomeguatrib is a nontoxic low-molecular weight pseudosub-
strate that has the ability to inactivate MGMT (Dolan et al, 1986,
1990). When used in combination with TMZ, lomeguatrib has been
shown to sensitise human tumour xenografts of the methylating
agent (Middleton et al, 2002). A phase I dose escalation study
previously conducted using lomeguatrib/TMZ combinations
demonstrated that intravenous administration of 10mgm
 2
lomeguatrib decreased levels of AGT in peripheral blood
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smononuclear cells (PBMC) and all tumours by over 95% (Ranson
et al, 2006). Consistent and complete depletion of MGMT activity
required 40mg lomeguatrib when the drug was administered orally
– after 20mg only 56% of patients showed total depletion in PBMC.
Lomeguatrib was well-tolerated up to 80mgm
 2 in the phase I
study (twice the proposed dose level in the current study), with no
clear toxicity associated with the administration of the drug alone
(Ranson et al, 2006). As consistent and complete depletion of
MGMT activity was achieved with 40mg oral lomeguatrib, a higher
dose was not considered necessary in this trial. Consequently, we
did not consider that dose reductions in lomeguatrib were
required. Toxicity observed with the lomeguatrib/TMZ combina-
tion was qualitatively similar to that observed with TMZ alone.
One patient with colorectal cancer experienced a 450% drop in
carcinoembryonic antigen (CEA) in the course of treatment in the
phase I trial. With 40mgday
 1 lomeguatrib p.o., the maximum-
tolerated dose of TMZ was 125mgm
 2, and these were the starting
doses for the current study.
Preclinical studies and the phase I trial provide evidence to
suggest that the combination of lomeguatrib and TMZ could
improve upon the modest activity of the methylating agent alone.
The primary study objective was to evaluate tumour response rates
to lomeguatrib and TMZ in patients with metastatic colorectal
cancer, with secondary aims of describing time to progression and
the safety and tolerability of the combination. Other objectives
were to evaluate the biochemical response using CEA levels and to
describe the pharmacokinetic and pharmacodynamic effects of
lomeguatrib.
MATERIALS AND METHODS
Patient selection
Patients with histologically proven metastatic colorectal cancer
were eligible for the study, provided that they had not previously
received more than two systemic chemotherapy regimens. Other
requirements included measurable disease; age 418 years; Eastern
Cooperative Oncology Group performance status of 0 or 1; life
expectancy 412 weeks; adequate bone marrow and biochemical
function (haemoglobin 410gdl
 1, white blood cells 43 10
9/l,
absolute neutrophil count 41.5 10
9/l, platelets 4100 10
9/l);
creatinine p1.25 upper limit of normal (ULN); bilirubin p1.25
ULN; AST p5 (metastases to liver) or 2  ULN.
Patients were excluded if within 4 weeks of previous therapy;
pregnant or nursing; still recovering from surgery; considered
poor medical risks due to a serious, uncontrolled medical disorder,
nonmalignant systemic disease or active, uncontrolled infection;
had known CNS metastases, had a history of seizures, were
on antiepileptic medication or had previously received an
O
6-alkylating agent.
The study was conducted in accordance with the principles of
the International Conference on Harmonisation of Good Clinical
Practice guidelines and the Declaration of Helsinki. The trial was
approved by an independent ethics committee according to
national and local requirements at each trial centre. All patients
gave informed written consent.
Study design and statistical considerations
This was a multi-centre open study to determine the response rate
to lomeguatrib and TMZ. We aimed to recruit 30 patients with
inoperable stage IV metastatic colorectal cancer. The sample size
was selected on the basis that 30 patients would ensure that the
standard error of the observed response rate was less than or equal
to 0.1 and permit a satisfactory estimate of response rate, but
incorporated an early stopping rule according to the method of
Gehan, with the response rate of interest set at 20%. Descriptive
statistics were generated for efficacy, toxicity, pharmacokinetic
and pharmacodynamic end points. The median time to progres-
sion was estimated using Kaplan–Meier survival curves. Patients
who had not progressed by the end of the study or who withdrew
prior to progression were censored for the analysis.
Drug administration
Lomeguatrib enteric-coated 10mg capsules were obtained from
Kudos Pharmaceuticals (Cambridge, UK), and TMZ purchased
from Schering Plough Ltd (Welwyn Garden City, UK) as 5, 20, 100
and 250mg capsules.
Patients received lomeguatrib 40mgday
 1 p.o. for 5 consecutive
days every 4 weeks for up to six cycles. Temozolomide was
administered at 125mgm
 2day
 1 p.o. 2h after lomeguatrib.
Patients fasted for 1 and 2h before and after TMZ and lomeguatrib
respectively.
Retreatment was permitted if the absolute neutrophil count was
X1.5 10
9/l, the platelet count X75 10
9/l and any other toxicity
had resolved to grade I or better. A treatment delay of up to 2
weeks was allowed for resolution of drug-related toxicity. Dose
reductions in TMZ were mandated in the event of grade IV
haematological toxicity, grade III toxicity lasting 7 or more days or
any grade III or IV nonhaematological toxicity. These were in
increments of 25 or 50mgm
 2day
 1 according to the type of
toxicity encountered. The need for doses of TMZ below
75mgm
 2day
 1 required the patient to be removed from the
study. Patients could be also withdrawn from the study for
progressive disease, serious violation of the study drug protocol or
withdrawal of consent.
Evaluation of response and toxicity
All eligible patients who received any part of the treatment were
considered assessable for response and toxicity. Patients were
assessed for adverse events at each attendance. Physical exam,
performance status and vital signs were recorded at the beginning
of each treatment cycle. Complete blood count was checked prior
to treatment and on days 14, 21 and 28, with blood chemistry
tested on days 1, 14 and 28. Adverse events were graded according
to the National Cancer Institute-Common Toxicity Criteria
(NCI-CTC) version 2.0. Tumour response was assessed every
second cycle based on clinical and radiological findings in
accordance with the RECIST criteria.
Pharmacodynamic and pharmacokinetic assays
These were performed in subset of patients. Samples for PBMC
MGMT activity were obtained prior to treatment on day 1 of cycle
1, and at 2, 4, 6, 8 and 24h after dosing in four patients. A total of
5–10ml of venous blood was collected into tubes containing 100ml
0.5 M EDTA and stored on ice for a maximum of 4h prior to
isolation of PBMC and analysis of MGMT. For pharmacokinetics,
two 5-ml venous blood samples were drawn predose, and at 0.5, 1,
2, 3, 4, 6 and 8h after dosing on days 1 and 5 of cycle 1 in nine
patients, for determination of lomeguatrib and TMZ concentra-
tions according to previously published methods (Watson and
Margison, 2000).
RESULTS
Nineteen patients were recruited to the study between September
2003 and January 2004. All had stage IV colorectal cancer and had
received prior chemotherapy, as described in Tables 1 and 2. Nine
patients had one prior chemotherapy treatment for metastatic
disease and nine had two previous regimens. A further patient had
three prior chemotherapy treatments but was enrolled, as the first
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sof these had been given 10 years previously, prior to resection of a
hepatic metastasis. Five patients had undergone radiotherapy, as
either adjuvant (three) or palliative (two) treatment. All but one
patient had undergone surgery for their disease.
All the patients received treatment as defined in the protocol,
although two individuals missed partial doses during cycle 1 and
cycle 4 respectively. A further patient took all the medication due
in cycle 1, but not according to the recommended schedule.
Treatment efficacy
None of the patients responded to treatment. Three patients had
stable disease: one each progressed after three and four cycles of
treatment, and the other remained progression-free at the end of
all six cycles of lomeguatrib and TMZ. No fall in CEA was observed
in any patient. Median time to progression was 50 days (95%
confidence interval 47–60 days).
Safety
All of the patients experienced adverse events related to treatment
(Table 3), but these were for the most part mild to moderate in
severity with the exception of thrombocytopaenia and anaemia
(Table 3). One patient experienced rectal bleeding while thrombo-
cytopaenic and required a platelet transfusion. One other patient
required a platelet transfusion, and growth factor support was
administered to one patient due to ongoing grade IV neutropaenia.
One patient died while on treatment. He was admitted after
receiving cycle 2 with increasing right upper quadrant pain,
shortness of breath, dizziness and mild confusion. These were not
considered related to study treatment and the patient was
considered to be experiencing disease progression based upon a
chest radiograph. He developed grade IV neutropaenia the
following day, which was considered highly probable in relation
to the study treatment, however, this was not treated due to the
patient experiencing disease progression. He died 2 days later from
disease progression and had no clinical evidence of infection at the
time of death.
Forty-nine cycles of lomeguatrib and TMZ were delivered
overall. Eleven cycles had to be delayed to allow recovery of
neutropaenia and/or thrombocytopaenia, and two more to
accommodate patients’ domestic arrangements. Dose reductions
in TMZ were required for nine patients (two reductions in one
case), all as a consequence of haematological toxicity.
Pharmacokinetics and pharmacodynamics
Pharmacokinetic samples for lomeguatrib (Table 4) and TMZ (data
not shown) were obtained in nine randomly selected patients. No
differences were apparent in parameters measured on day 1 as
compared with those from day 5 for either drug. The data for TMZ
were consistent with previous studies, including a recent phase II
trial of the combination in melanoma (Ranson et al, 2006, 2007).
O
6-Methlylguanine-DNA alkyltransferase activity in PBMC in four
patients fell rapidly after dosing with oral lomeguatrib with 92%
depletion, compared with pretreatment values, at 2h and no
detectable activity at all subsequent time points was observed.
O
6-Methlylguanine-DNA alkyltransferase activity was not analysed
in more patients as a similar study using lomeguatrib and TMZ in
melanoma patients demonstrated the same results in over 40
patients (Ranson et al, 2007).
DISCUSSION
The primary objective of the study was to evaluate the tumour
response rate after administration of the combination of
lomeguatrib and TMZ in patients with stage IV metastatic
colorectal carcinoma. The original recruitment target was 30
patients, but the absence of responses coupled with evidence from
other studies, which suggests that the dosing regimen of
lomeguatrib was inadequate, led to the closure of the trial after
19 patients had been included (Ranson et al, 2006).
Table 1 Patient characteristics
N¼19 (%)
Median age, years (range) 59 (39, 81)
Male/female 14/5
Site of primary tumour
Caecum 6 (32)
Colon 5 (26)
Rectum 4 (21)
Not specified 4 (21)
Performance status (ECOG)
0 5 (26)
1 14 (74)
Prior chemotherapy
Fluoropyrimidines 19 (100)
Irinotecan 15 (79)
Oxaliplatin 12 (63)
Others
a 3 (16)
ECOG¼Eastern Cooperative Oncology Group.
aHydroxyurea/5-FU (1); low-dose
cyclophosphamide/methotrexate/celecoxib (2).
Table 2 Details of previous chemotherapy treatments
Prior chemotherapies N¼19 (%)
5-fluorouracil 10 (52.6)
Capecitabine 1 (5.3)
Irinotecan 15 (78.9)
Folinic acid 12 (63.2)
Calcium folinate 3 (15.8)
Leucovorin 1 (5.3)
Leucovorin calcium 1 (5.3)
Oxaliplatin 12 (63.2)
Cyclophosphamide 2 (10.5)
Methotrexate 2 (10.5)
Celecoxib 1 (5.3)
Calcium levofolinate 1 (5.3)
Tyrosine hydroxylase inhibitors 1 (5.3)
Table 3 Adverse events considered to be related to study treatment
All adverse events
n¼19 (%)
G3/4 adverse
events (%)
Thrombocytopaenia 68.0 52.7
Neutropaenia 52.6 63.7
Febrile neutropaenia 5.3 5.3
Anaemia 21.1 10.5
Nausea 68.4 0
Vomiting 26.3 5.3
Constipation 52.6 21.1
Diarrhoea 21.1 0
Dyspepsia 5.3 0
Fatigue 26.3 0
Pyrexia 15.8 0
Anorexia 42.1 0
Headache 36.8 0
Alopecia 5.3 0
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sThe best response was stable disease, but only one patient
sustained this for the full 6 months of treatment. The majority of
patients experienced disease progression at cycle 2, such that the
median time to progression was only 50 days. Half of our patients
were having their second line of therapy, where response rates of
20–30% are obtainable, and the other half their third or fourth line
of treatment where responses are seen in 10–15%.
The adverse-effect profile of this combination of lomeguatrib
and TMZ did not differ significantly from that associated with
TMZ alone, although haematological toxicity was more pro-
nounced. The majority of adverse events were mild (CTC grades I
and II). All patients experienced adverse events of the gastro-
intestinal system, of which the majority were considered related to
the study treatment. Blood dyscrasias were the second most
frequently observed adverse event, and all were considered related
to the study treatment. Of the grade III and IV adverse events,
most were haematological. A general deterioration in performance
status was observed in the patient population during the course of
participation in the trial, consistent with patients with metastatic
cancer whose disease was progressing.
The addition of lomeguatrib did not appear to alter this profile
significantly, but it is likely to have triggered adverse haematolo-
gical events at a lower dose of TMZ. This has been found in the
original dose escalation phase I trial as well as in a comparative
trial in melanoma (Ranson et al, 2006, 2007).
This study has demonstrated that the drug combination used
was not efficacious in this indication but was safe with a
comparable adverse event profile to TMZ alone with the exception
of enhanced haematological toxicity. Potential reasons for this
lack of efficacy include the wrong doses of TMZ and lomeguatrib
and perhaps more importantly, the fact that colorectal cancer is
not considered to be particularly sensitive to TMZ (Spiro et al,
2001). It may be that other downstream mechanisms of resistance
are to blame. For example, deficient MMR leads to tolerance of
methylation damage, and changes to the apoptotic machinery have
been linked to TMZ resistance (Madhusudan and Middleton,
2005). In a melanoma study with the same regimen, tumour biopsy
analysis suggested early recovery of MGMT activity, within 24h,
even when lomeguatrib doses were increased to 60 and 80mg per
day (Ranson et al, 2006). The methylation lesion at the O
6 position
in guanine leads to cell death only after one or two rounds of DNA
replication. It therefore seems advisable in future to use higher
doses of lomeguatrib than we have in this trial, and to continue
dosing for some days following the last administration of TMZ.
Our findings are consistent with those from other trials
involving MGMT pseudosubtrates (Friedman et al, 1998, 2000;
Quinn et al, 2002; Gajewski et al, 2005; Ranson et al, 2006). In trials
performed so far with O
6-benzylguanine (O
6-BG) and lomeguatrib,
there has been enhancement of toxicity, particularly myelo-
suppression when used in combination with alkylating agents.
Consequently, only about 20% of the standard dose of alkylating
agent can be administered when combined with O
6-BG, and with
lomeguatrib, patients tolerate approximately two-thirds of the
standard drug dose. To date, superior efficacy with this approach
has not been demonstrated and it seems unlikely that increased
responses to alkylating agents in most tumours will be seen while
the problem of enhanced toxicity remains.
On the current evidence, further trials of lomeguatrib and TMZ
in metastatic colorectal cancer are not warranted. However, MGMT
depletion has been found to enhance the cytotoxicity of classic
alkylators, such as cyclophosphamide and topoisomerase I inhibi-
tors, such as irinotecan (Friedman et al, 1999, 2002). In the case of
irinotecan, sensitivity to its active metabolite SN-38 is inversely
correlated with MGMT expression in cell lines (Okamoto et al, 2002).
Interestingly, there is schedule-dependent synergy between TMZ and
irinotecan, likely mediated through the effects of O
6-methylguanine
on the kinetics of the interaction between topoisomerase 1 and DNA.
O
6-Methlylguanine-DNA alkyltransferase depletion further enhances
the cytotoxicity of TMZ and irinotecan (Sabharwal and Middleton,
2006). A trial combining lomeguatrib and irinotecan in metastatic
colorectal cancer is ongoing.
In conclusion, this combination of lomeguatrib and TMZ is not
efficacious in metastatic colorectal cancer, which is probably a
reflection of the insensitivity of colorectal cancer to TMZ. Results
from an ongoing trial combining irinotecan and lomeguatrib will
be interesting.
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